Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours

Endocrine Regulations

Volumn 35, Issue 1, 2001, Pages 9-16

  Kolomecki, Krzysztof ^a   Stepien, Henryk ^a   Bartos, Magdalena ^a   Kuzdak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adrenal tumour; Angiogenesis; Metalloproteases; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; GELATINASE A; LYMPHOKINE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VASCULOTROPIN A;

ADENOMA; ADRENAL CORTEX TUMOR; ADRENAL TUMOR; ADRENALECTOMY; ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; TUMOR RECURRENCE;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ADULT; AGED; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHEOCHROMOCYTOMA; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035287650     PISSN: 12100668     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. BAILEY CJ, HEMBRY RM, ALEXANDER A, IRVING MH, GRANT ME, SHUTTLEWORTH CA: Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B and collagenase in Crohn's disease and normal intestine. J Clin Pathol 47, 113-116, 1994
2. BLALOCK HM: Social Statistics, p. 96. Mc Graw-Hill Book Company Inc New York, Toronto, London 1960
3. BOUCK N, STELLMACH V, Hsu S.C.: How tumors become angiogenic. Adv Cancer Res 69: 135-174, 1996.
4. BROWN LF, BERSE B, JACKMAN RW: Expression of vascular premeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53, 4727-4735, 1993
5. BROWN LF, BERSE B, JACKMAN RW: Expression of vascular permeability factor (VEGF) and its receptors in breast cancer. Human Pathol 26, 886-891, 1995
6. BROWN LF, BERSE B, JACKMAN RW, TOGNAZZI K, MANSEAN EJ, DVORAK HF, SENGER DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinoma. Am J Pathol 143, 1255-1262, 1993
7. BROWN PD, BLOXIDGE RE, STUART NSA, GATTER KC, CORMICHAEL J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Invest 85, 574-578, 1993
8. CHAMBERS AF, MATRISIAN LM: Changing view of the role of matrix metalloproteinases in metastases. J Natl Cancer Inst 89, 1260-1270, 1997
9. D'AMORE PA, SHIMA DT: Tumor angiogenesis: a physiological process pr genetically determined? Cancer Metastasis Rev 15, 205-212, 1996
10. DVORAK HF: Tumors: wounds that do not heal. New Engl J Med 315, 1650-1659, 1986
11. FERRANE N: Vascular Endothelial Growth Factor. Eur J Cancer 14, 2413-2422, 1996
12. FOLKMAN J, WATSON K, INGBERG D, HANAHAN D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61, 1989
13. GARATTI GG, CIAVATTINI A, LUCARINI: Expression of vascular endothelial growth actor related 72-kilodalton metalloproteinase immunostainig in patients with serous ovarian tumors. Cancer 85, 2219-2225, 1999
14. GOHJI K, FUJIMOTO N, KOMIYAMA T: Evaluation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78, 2379-2385, 1996
15. JOHNSON MD, KIM HR, CHESLER L, TSAO-WU G, BOUCK N, POLVERINI PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160, 194-202, 1994
16. JUNG K, NOWAK N, LEIN M, PRIEM F, SCHUORR D, LOENING S.A: Matrix metalloproteinase-1 and -3, tissue inhibitor of MMP-1 and the complex of metalloproteinases- 1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74, 220-229, 1997
17. KASPERLIK-ZALUSKA A, ROSLONOWSKA E, TOLLOCZKO T: Incidentally found adrenal tumours: observation of 212 cases. J Endocrinol Invest 19, (Suppl. 31), 25-31, 1996
18. KOHN EC, JACOBS W, KIM YS, ALEKSANDRO R, STETLER-STEVENSON WG, LIOTTA LA: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type Iv collagenase, gelatinase A). J Biol Chem: 269, 21505-21515, 1994
19. KOLOMECKI K, POMORSKI L, KUZDAK K, NAREBSKI JM, WICHMAN R. The surgical treatment of adrenal gland tumors - incidentaloma. Neoplasma 2, 131-134, 1999
20. KRAFT A, WEIDEL K, OCHS A: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85, 178-187, 1999
21. KUGLER A, HEMMERLEIN B, TIIELEN P, KALLERHOFF M, RADZUN HJ, RINGERT RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 16, 1914-1918, 1998
22. LEVY TD, CIOCE V, SOBEL ME: Increased expression of the Mr 72 000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51, 439-444, 1991
23. LIOTTA LA, STEEG PS, STETLER-STEVENSON WG: Cancer metastasis and angiogenesis: an imbalance of possitive and negative regulation. Cell 64, 327-336, 1991
24. MAEDA K, CHUNG YS, OGAWA Y: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77, 858-863, 1990
25. MATTERN J, KOOMAGI R, VOOM M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73, 931-934, 1996
26. NAYLOR MS, STAMP GW, DAVIES BD, BALKWILL FR: Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58, 50-56, 1994
27. Nuovo GJ, MAC CONNELL PB, SIMSIR A, VALEA F, FRENCH DL: Correlation of the in situ detection of polymerase chain reaction - amplified metalloprotein-ase complementary DNAs and their inhibitors with prognostic in cervical carcinoma. Cancer Res: 55, 267-275, 1995
28. RAY JM, STELLER-STEWENSON WG: The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J 7, 2062-2072, 1994
29. TOI M, TONIGUCHI T, YAMAMOTO Y, KURISAKI T, SUZUKI H, TOMINAGA T:. Clinacal significance of the determination of angiogenic factors. Eur J Cancer 14, 2513-2519, 1996
30. UNEMORI EN, FERRARA N, BAUER EA, AMENTO EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153, 557-562, 1992
31. VIGLIETTO G, MAGLIONE D, RAMBALD M: Upregulation of vascular growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11, 1569-1579, 1995
32. WILLENBROCK F, MURPHY G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 150, 165-170, 1994
33. WOJTOWICZ-PRAGA S, DICKSON RB, HAWKINS MJ: Matrix metalloproteinase inhibitors. Investigat New Drug 15, 61-75, 1997
34. WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M: Phase I trial mARI-MAStat, a novel matrix metalloproteinase inhibitor administered orally to patients with advanced lung cancer. J Clin Oncol 16, 2150-2156, 1998
35. YAMAMOTO Y, Toi M, KONDO S: Concentrations of vascular endothelial growth factor in sera of normal control and cancer patients. Clin Cancer Res 2, 821-826, 1996
36. ZUCKER S, LYSIK RM, ZARRABI MH, MOLL U: M 92 000 Type IV collagenase is increased in plasma of patients with colon breast cancer. Cancer Res 53, 140-146, 1993
37. ZUCKER S, LYSIK RM, ZARRABI HM: Plasma assay of matrix metalloproteinases and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann NY Acad Sci 732, 248-262, 1994